Last updated: February 13, 2026
What is NDC 00904-7415?
NDC 00904-7415 refers to the drug Rybelsus (semaglutide), indicated for type 2 diabetes management. It is a glucagon-like peptide-1 (GLP-1) receptor agonist, administered orally, and marketed by Novo Nordisk. FDA approval was granted in September 2019, positioning Rybelsus as a first oral GLP-1 therapy.
Market Size and Growth
Current Market Presence
- Sales Revenue (2022): Approximately $1.1 billion in the U.S. (IQVIA, 2023).
- Market Share: Rybelsus holds around 12% of GLP-1 receptor agonist prescriptions in the U.S.
- Competitive Position: Competes with injectable GLP-1s like Ozempic (semaglutide injection) and Trulicity (dulaglutide).
Growth Drivers
- Increasing prevalence: U.S. adult type 2 diabetes cases estimated at 37 million, 90-95% of whom require GLP-1 therapy.
- Patient preference shift: Oral administration favors adherence, driven by patients' aversion to injections.
- Expanding indications: Ongoing research for weight management and cardiovascular risk reduction widens market scope.
Market Projections (2023–2028)
| Year |
Estimated Sales (USD) |
CAGR (Compound Annual Growth Rate) |
Notes |
| 2023 |
$1.3 billion |
18% |
Growing adoption, new indications. |
| 2024 |
$1.52 billion |
17.5% |
Continued uptake, marketing expansion. |
| 2025 |
$1.78 billion |
17% |
Intro of competitive oral GLP-1s. |
| 2026 |
$2.08 billion |
16.5% |
Market saturation nearing. |
| 2027 |
$2.43 billion |
15.5% |
Competitive pressures increase. |
| 2028 |
$2.83 billion |
14.5% |
Maturity phase, price stabilization. |
Competitive Landscape
| Product |
Delivery Method |
Market Share (2022) |
Key Differentiator |
Price Positioning |
| Rybelsus |
Oral tablet |
12% |
First oral GLP-1, better patient compliance |
Premium, but competitive pricing |
| Ozempic |
Injection |
40% |
Strong efficacy, less frequent dosing |
Higher, premium segment |
| Trulicity |
Injection |
28% |
Weekly dosing, well-established brand |
Similar to Ozempic |
| Tirzepatide (Mounjaro) |
Injectable |
Emerging (post-2022) |
Dual GIP/GLP-1 action, high efficacy |
Higher pricing, premium segment |
Price Analysis and Projections
Current Pricing
- Average wholesale price (AWP): Approximately $740 for a 30-day supply (28 tablets at 14 mg dose).
- Net prices: Estimated at 30-40% discounts to AWP due to rebates, resulting in around $500–$550 per month.
Price Trends
- Initial entrance price (2019): Approximately $690 per month.
- Recent adjustments: Slight increases up to $740 due to inflation, formulation improvements, and market dynamics.
- Price elasticity: Relatively inelastic because of high demand and lack of direct substitutes.
Future Price Outlook
| Year |
Estimated Wholesale Price (USD/month) |
Rationale |
| 2023 |
$750 |
Standard cost inflation and market positioning. |
| 2024 |
$755 |
Competitive pressures may prevent significant increases. |
| 2025 |
$760 |
Introduction of biosimilars or generic options could influence pricing. |
| 2026 |
$765 |
Slight downward pressure possible with increased competition. |
| 2027 |
$770 |
Premium positioning maintained if brand loyalty persists. |
Regulatory and Pricing Factors
- Pricing control: U.S. CMS and PBMs exert influence through formulary negotiations.
- Rebates and discounts: Deep negotiations impact net pricing.
- Potential biosimilar entry: Although no biosimilar announced as of Q1 2023, patent litigation and legal extensions may alter the landscape around 2027–2028.
Key Risks and Opportunities
Risks:
- Patent litigation and potential biosimilar development threaten pricing power.
- Competitive emergence from oral SGLT2 inhibitors and future oral peptide therapies.
- Policy shifts toward price regulation might pressure margins.
Opportunities:
- Expansion into weight management and cardiovascular risk reduction markets.
- Enhancing adherence through improved oral formulations and patient education.
- Strategic partnerships with payers for favorable formulary access.
Key Takeaways
- Market Size: US sales of Rybelsus are projected to reach nearly $2.8 billion by 2028.
- Growth Rate: CAGR of approximately 14–18% over the next five years.
- Pricing Trend: Wholesale prices remain stable, slightly increasing, with unit prices around $750–$770/month.
- Competitive Positioning: Dominated by injectable rivals, though Rybelsus's oral formulation provides differentiation.
- Risks: Patent challenges and market competition may limit pricing power.
FAQs
Q1: How does Rybelsus compare price-wise to injectable GLP-1s?
A: Oral Rybelsus is generally priced similarly but may have slightly lower costs due to less administration infrastructure; actual net costs vary based on rebates.
Q2: What factors could influence future price declines?
A: Entry of biosimilars, increased generic competition, and policy interventions could lower prices.
Q3: How significant is patient adherence for Rybelsus sales?
A: High adherence depends on ease of use, cost, and physician prescribing behaviors; oral administration potentially improves retention.
Q4: Are there upcoming regulatory changes that could impact prices?
A: CMS price negotiations and drug importation policies could exert downward pressure, particularly if biosimilars enter the market.
Q5: What are the primary markets for Rybelsus outside the U.S.?
A: Europe, Japan, and other advanced markets are expanding, but U.S. remains the key revenue driver due to early adoption and high diabetes prevalence.
References
- IQVIA. (2023). NPA database.
- FDA. (2019). Approval of Rybelsus (semaglutide) for type 2 diabetes.
- MarketWatch. (2023). Rybelsus sales figures.
- CB Insights. (2022). Oral GLP-1 market analysis.
- Pharm exec. (2023). Pricing trends in diabetes therapeutics.
